Barbara holds a PhD in Biomedical Sciences (Ghent University, Belgium) and received training in Conceptual Selling (Miller Heiman) and Digital Transformation (Vlerick Business School, Belgium). In 2020, Barbara was nominated as one of the 50 most inspiring women in Belgian Tech.
She acquired Sales and Marketing, Business Development and Management skills in an international context within companies providing life science services. She was the co-founder and CEO of the healthtech company Akcelis that developed and commercialized tools and services for digital patient recruitment in clinical trials. As a pioneer within Europe, Akcelis became a trusted partner of top 5 pharma and biotech companies managing large international projects across Europe. In 2020, this scale-up was acquired by the Pivotal, a full-services contract research organization for the healthcare industry across Europe. For two years, Barbara was Director Patient Journey at Pivotal before continuing her career as an independent consultant. In May 2022, she joined Vivactis HM3A.

Sacha is an Industrial Pharmacist, and graduated from Leuven as a Master in Drug Development in 2019. She followed an Interdisciplinary Program in Healthcare Innovation and received training on Skill Development in Applied Marketing Track and Communication Track (AFC Leuven). After her studies, she immediately started as an independent consultant, developing skills in Quality Assurance, Pharmacovigilance or Regulatory Affairs through the Benelux and already working and acquiring experiences in Market Access through the Vivatis HM3A-activities. In 2021, Sacha obtained the agreement from the authorities as a recognized and authorized Responsible Person for Information and Publicity. Since 2021, co-founder and CEO of the company “KSPS”, a consultancy bureau specialized in the healthcare industry across Benelux and committed to deliver value and quality through objective and effective advice on Quality Assurances, Regulatory Affairs, Publicity and Compliance or Vigilance, for medicinal products and medical devices, cosmetics, food supplements and even biocides. She is working hand-in-hand with Vivactis HM3A.

Olivier is Associate Professor of Health Economics at the Department of Public Health Sciences, Faculty of Medicine, University of Liège in Belgium. He is also an invited lecturer at the Department of Pharmacy and the Department of Biomedical Sciences, Faculty of Medicine, University of Namur in Belgium. He lectures in health economics (theory & applied modeling), decision sciences and pharmacoepidemiology. Olivier holds a PhD in Public Health Sciences from the University de Liège and an MSc in Mathematical Economics from the University of Paris I – Panthéon Sorbonne. His research interests include financial modeling of patients and market access strategies and population-based modeling. Olivier has nearly 20 years of experience as an economic and financial modeler gained in the private sector at IMS Health (now IQVIA), Bristol-Myers & Squibb and GlaxoSmithKline Vaccines. Olivier has designed numerous economic and financial models across a broad spectrum of disease areas and his experience spans all types of healthcare technologies including drugs, biologics, vaccines, devices, and diagnostics.

Mark Nuijten is medical doctor, health economist, market access and pricing consultant, valuation economist,  and healthcare policy journalist.  Mark Nuijten has a varied career in the health academic and business environment.  He is pursuing development of economic modelling and broadening its application in health care and finance. His reimbursement dossiers, incl. cost-effectiveness and BIA models, successfully contributed to positive reimbursement decisions by health authorities in many countries, (for example, NICE in England, SMC in Scotland, TLV in Sweden, CADTH in Canada, Zin in The Netherlands, RIZIV/INMAI in Belgium).

He is academic supervisor of PhD programs at the Universities of Maastricht and Groningen in The Netherlands and founder of the ISPOR Special Interest Group on nutrition-economics. Since 2017 he is Adjunct Professor at ITU (Istanbul Technical University) in International Healthcare Assessment and Valuation.

Wil Toenders was trained as a pharmacist and, in his minor in general practice, has conducted research into the prescribing behavior of general practitioners. After working as a practice pharmacist for some years, he specialized in pharmacotherapy. He was, among other things, editor-in-chief of the Dutch Drug Bulletin and editor of the Pharmacotherapeutic Compass. His last governmental job was as head of drug assessment at the National Health Care Institute, responsible for the advices to the Ministry of Health about the therapeuitic value, budgetimpact and cost-effectiveness of all new medicines. For more than thirteen years he has gained experience as an independent consultant in the field of the reimbursement of medicines, as of 1 January 2023 from Advamedic.

Géraldine is Doctor of Veterinary Medecine. She also holds a MSc in Public Health Sciences with a major in Epidemiology and Health economics. She is currently following the Master in Medicine (University of Liege). She brings expertise in infectious diseases and antibiotics. Moreover, she is passionate about internal medicine and patient care. She joined Vivactis HM3A in July 2022.

Lina graduated with a Master’s degree in Pharmaceutical Sciences from the Université libre de Bruxelles (ULB) in Belgium. She completed her master thesis with a “magna cum laude” in the field of digital health. The subject of the thesis was “The Introduction of Innovative Digital Health Technologies in the Belgian Healthcare System – A comparison with other European Healthcare Systems.” This master thesis focuses on three aspects regarding the introduction of digital health technologies, more specifically the implementation of Electronic Health Records, Telemedicine and Mobile apps within the healthcare system of Belgium, France and Germany. It also included a description of the new initiatives presented by the European commission regarding the European Health Data Space. Lina was an intern for a year and a half within the Health Economic & Market Access department of one of the top 10 global pharmaceutical companies within the Medical Devices division. She also holds a Specialized Master in Entrepreneurship and Innovation from Rome Business School. Lina joined Vivactis HM3A in May 2023.

Christine Juliam started her career in clinical research at MSD in Belgium before moving into product management, and subsequently into sales, marketing, and business planning responsibilities. In July 1996, she started to work for Abbott Belgium as director of the pharmaceutical product division, and joined Nycomed as managing director Belgium/Luxembourg in 2006. From 2011 onwards, she was region head for France, the Netherlands, Belgium, and Luxembourg for Nycomed, which was acquired by Takeda in the same year. Subsequently, Ms. Juliam managed Takeda Italy and France as country manager between 2013 and 2017. In 2021-2022, she was general manager at Orifarm. Christine Juliam has a Doctor’s Degree of Medicine from the University of Ghent, a License in Marketing from St. Aloysius College in Brussels, a Master in Management from Solvay Commercial School in Brussels, and an MBA from Northwestern University.

Click here to learn more about our team located in Spain.

Vivactis Weber has a leading position in Spain for global pharma, biotech, and medical device companies with a primary expertise in several therapeutic areas, including rare disease and oncology. With its team of more than 25 highly qualified employees Weber owns more than 15 years of experience and carried out more than 230 projects. The company has an impressive track record in Health Outcome Research including Social Return On Investment (SROI) projects, a type of economic evaluation with the possibility of involving patients. Weber is also a leader in Multicriteria Decision Analysis (MCDA) projects, a structured process that offers greater flexibility to incorporate multiple objectives in comparison to cost-effectiveness analysis or cost-utility analysis. In addition, Weber Foundation allows leading projects in collaboration with patient associations and public entities in order to improve the patients engagement process.

Thibault Colin started his career as an economic analyst specializing in the macroeconomic approach to business and government relations in both France and Europe. He then moved on to social protection and life insurance and then to public affairs and market access consulting for healthcare products. He holds an MSc in Economics from Sciences Po Bordeaux and is studying public health at the Paris School of Medicine. Driven by health issues and knowledgeable of regulatory, political, social and financial obligations and opportunities, he brings his expertise in healthcare systems, health democracy and patient value. Thibault joined Vivactis in December 2022.